Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price target remains the same with $284.00.
Michael Ulz has given his Hold rating due to a combination of factors related to Alnylam Pharmaceuticals’ current position and future prospects. The company has shown significant progress in its pipeline, particularly with its ATTR franchise, which includes promising updates on vutrisiran and plans for a Phase 3 program for nucresiran. However, despite these advancements, the focus remains on the near-term approval of vutrisiran for ATTR cardiomyopathy, which is expected to expand its market potential but still awaits regulatory approval.
Moreover, while Alnylam’s broad pipeline shows potential with various programs in cardiovascular and neuroscience areas, as well as new clinical programs in bleeding disorders and type 2 diabetes, the realization of these opportunities is more long-term. The company’s ambitious goal to deliver RNAi therapeutics to all major tissue types by 2030 adds to the potential, but the timeline and execution risks associated with these developments contribute to the Hold rating. Overall, while the pipeline is promising, the current market conditions and pending approvals suggest a cautious approach.
According to TipRanks, Ulz is an analyst with an average return of -2.9% and a 36.23% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Vir Biotechnology.
In another report released on February 13, Leerink Partners also reiterated a Hold rating on the stock with a $200.00 price target.